» Articles » PMID: 33414393

Cell-cycle Arrest and Senescence in TP53-wild Type Renal Carcinoma by Enhancer RNA-P53-bound Enhancer Regions 2 (p53BER2) in a P53-dependent Pathway

Overview
Journal Cell Death Dis
Date 2021 Jan 8
PMID 33414393
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

TP53 is a classic tumor suppressor, but its role in kidney cancer remains unclear. In our study, we tried to explain the role of p53 in kidney cancer through the p53-related enhancer RNA pathway. Functional experiments were used to explore whether P53-bound enhancer regions 2 (p53BER2) has a role in the cell cycle and senescence response of TP53-wild type (WT) renal cancer cells in vitro or vivo. RNA-sequencing was used to identify the potential target of p53BER2. The results showed that the expression level of P53BER2 was downregulated in renal cancer tissues and cell lines, further dual-luciferase experiments and APR-256-reactivated experiments showed p53BER2 expresses in a p53-dependent way. Moreover, knockdown p53BER2 could reverse nutlin-3-induced cytotoxic effect in TP53-WT cell lines. Further exploration showed the downregulation of p53BER2 could reverse nutlin-3-induced G1-arrest and senescence in TP53-WT cell lines. What is more, the knockdown of p53BER2 showed resistance to nutlin-3 treatment in vivo. Additionally, we found BRCA2 could be regulated by p53BER2 in vitro and vivo; further experiment showed p53BER2 could induce cell-cycle arrest and DNA repair by mediating BRCA2. In summary, the p53-associated enhancer RNA-p53BER2 mediates the cell cycle and senescence of p53 in TP53-WT renal cancer cells.

Citing Articles

Role of epigenetics in paediatric cancer pathogenesis & drug resistance.

Leung J, Chiu H, Taneja R Br J Cancer. 2025; .

PMID: 40055485 DOI: 10.1038/s41416-025-02961-2.


Caspase 3 and caspase 7 promote cytoprotective autophagy and the DNA damage response during non-lethal stress conditions in human breast cancer cells.

Samarasekera G, Go N, Choutka C, Xu J, Takemon Y, Chan J PLoS Biol. 2025; 23(3):e3003034.

PMID: 39982959 PMC: 11882052. DOI: 10.1371/journal.pbio.3003034.


Downregulation of MerTK in circulating T cells of patients with non-proliferative diabetic retinopathy.

Bu S, Ling J, Wu X, Zhang L, Shi X, Huang L Front Endocrinol (Lausanne). 2025; 15():1509445.

PMID: 39845889 PMC: 11750652. DOI: 10.3389/fendo.2024.1509445.


Uncovering a new family of conserved virulence factors that promote the production of host-damaging outer membrane vesicles in gram-negative bacteria.

Goman A, Ize B, Jeannot K, Pin C, Payros D, Goursat C J Extracell Vesicles. 2025; 14(1):e270032.

PMID: 39840902 PMC: 11752146. DOI: 10.1002/jev2.70032.


Resistance mechanisms to immune checkpoint inhibitors: updated insights.

Alsaafeen B, Ali B, Elkord E Mol Cancer. 2025; 24(1):20.

PMID: 39815294 PMC: 11734352. DOI: 10.1186/s12943-024-02212-7.


References
1.
Imai Y, Strohmeyer T, Fleischhacker M, Slamon D, Koeffler H . p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol. 1994; 7(7):766-70. View

2.
Melo C, Drost J, Wijchers P, van de Werken H, de Wit E, Vrielink J . eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell. 2013; 49(3):524-35. DOI: 10.1016/j.molcel.2012.11.021. View

3.
Leveille N, Melo C, Rooijers K, Diaz-Lagares A, Melo S, Korkmaz G . Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA. Nat Commun. 2015; 6:6520. PMC: 4389233. DOI: 10.1038/ncomms7520. View

4.
Munro A, Lain S, Lane D . P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005; 92(3):434-44. PMC: 2362083. DOI: 10.1038/sj.bjc.6602358. View

5.
Zandi R, Selivanova G, Christensen C, Gerds T, Willumsen B, Poulsen H . PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res. 2011; 17(9):2830-41. DOI: 10.1158/1078-0432.CCR-10-3168. View